Patient preferences are critical for the successful development, regulation, and reimbursement of medical products and creating patient centric decision-making within the medical product lifecycle (MPLC). This thesis identified multiple systemic challenges preventing the systematic integration of patient preference studies into the MPLC. Greater methodological clarity is needed by key stakeholders before the information can be successfully incorporated into decision-making. Patient preferences can be measured through a variety of different preference elicitation and exploration methods and decision-makers are eager to discover which methods would be the most acceptable for market authorisation submissions or HTA/payer reimbursement decisions. This thesis appraised several methods and conducted a head-to-head empirical study. There is no ‘gold-standard’ patient preference elicitation or exploration method, but some methods have more promising features, and are more likely to meet decision-makers needs across the MPLC, such as the discrete-choice experiment (DCE). The development of methodologically sound patient preference studies is an important field of scientific research that will benefit the lives of patients.

M.P.M.H. Rutten-van Mölken (Maureen) , E.W. de Bekker-Grob (Esther)
Erasmus University Rotterdam
The research reported in this thesis was financially supported by The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Health Technology Assessment

Whichello, C.L. (2020, December 9). Patient Preferences throughout the Medical Product Lifecycle. Erasmus University Rotterdam. Retrieved from